chrisvoncsefalvay/vaers-outcomes huggingface dataset:
18 yo patient was seen for vaccine catch up schedule and due for 2nd dose of MMR and varicella.  The provider, recommended proquad which was given.  It was shortly after administration of the proquad that the clinic staff realized the patient was outside of the age range for proquad administration.   Mother of patient was notified of this error, mother of patient reports that after 3 days there were no adverse reactions to the Proquad administration
About 8:20 AM on 9/16/02, spouse telephoned and reported that 24 hours after his wife received her immunizations, she developed a large, red welt at injection site, low grade temperature and flu-like symptoms, lethargy.
This spontaneous report was received from a patient of unknown demographics regarding himself/herself. No pertinent medical history, concurrent conditions or concomitant mediations were reported. On 10-JUN-2015, the patient was vaccinated with an expired dose of ZOSTAVAX (1 time vaccine), dose route and frequency not reported. The outcome of expired product administered was unknown. Additional information has been requested.
Soreness in left arm at injection site; treated with Tylenol Between 24-48 hours after injection, I experienced body aches similar to flu symptoms; treated with Tylenol After 48 hours, all symptoms slowly subsided; continues treatment with Tylenol After 4 days, the only remaining symptom is very slight soreness at injection site
Swollen Injection site; Red injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (Swollen Injection site) and VACCINATION SITE ERYTHEMA (Red injection site) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Feb-2021, the patient experienced VACCINATION SITE SWELLING (Swollen Injection site) and VACCINATION SITE ERYTHEMA (Red injection site). At the time of the report, VACCINATION SITE SWELLING (Swollen Injection site) and VACCINATION SITE ERYTHEMA (Red injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included Ice.  No relevant concomitant medications were reported.
patient came in stating for first dose of COVID-19 vaccine.  reflected 1st dose.  Provider gave pfizer dose.  When support staff looked up pt. eligibility for incentive program in record showed pt. had J&J 3/28/21.  Pt. admitted to doing this because he heard pfizer was a better vaccine. incentive was not given.
Pain in her left arm, swollen and hard. Can't move with her arm. Rash on that spot.
Vaccine received on June 2, 2007, pt observed for 20 minutes after receiving vaccine, pt reported feeling strange one hour after vaccine, developed diarrhea followed by epigastric pain(felt like hole in the stomach) which started at inferior aspect of scapula on left side and radiated towards abdomen, pt felt like something went from her back thru the lower part of her heart to her epigastric area, pt also reports local redness of left deltoid
This spontaneous report was received from a physician refers to a patient of unknown age and gender. On 05-OCT-2012 the patient was vaccinated with a dose of PNEUMOVAX23 (lot # H013847, expiration date unknown) dose and route not reported. No concomitant medications were reported. The physician reported that the patient experienced adverse effects of malaise, fatigue, swelling, fever and under-arm pain. The date of birth was not available for this patient nor was the specific information about the patient. The patient did not recover from the reported events at the time of this report. Treatment was not given for the events. There were no laboratories diagnostic test performed. The patient sought medical attention by notifying the physician. The physician was enquiring if there had been an increase in reports of adverse effects from this lot of PNEUMOVAX23 and was it possible that this lot of PNEUMOVAX23 was contaminated. This is one of the several reports from the same reporter. Additional information has been requested.
Calf hurting; Right knee hurting; 70 days post first vaccine and forgot to get the second vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Calf hurting), ARTHRALGIA (Right knee hurting) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (70 days post first vaccine and forgot to get the second vaccine) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concomitant products included LOSARTAN for an unknown indication.  On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced PAIN IN EXTREMITY (Calf hurting), ARTHRALGIA (Right knee hurting) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (70 days post first vaccine and forgot to get the second vaccine). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Calf hurting), ARTHRALGIA (Right knee hurting) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (70 days post first vaccine and forgot to get the second vaccine) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Most recent FOLLOW-UP information incorporated above includes: On 06-Apr-2021: Special situation reported in follow-up.
Julissa received her 1st HPV vaccine on 4/11/07 (Merck 0263U), 2nd HPV vaccine on 7/5/07 (Merck 0279X), and her 3rd HPV vaccine on 7/11/08 (Merck 0279X).  She also received her MCV4 on 7/5/07 (Sanofi Pasteur u2222aa) and Tdap on 4/11/07 (GSK C2609AA).  At her annual physical on 8/21/08, she described dizzyness, headache, blurry vision, eye pain, and gait disturbance.  She subsequently had a head CT and head MRI.  The head MRI was suspicious for multiple sclerosis, and on 8/23/08 she was hospitalized at Brigham and Women's Hospital, which was a 7 day hospitalization and she was given the diagnosis of multiple sclerosis.  In retrospect, Julissa's mother feels that her symptoms described at her annual physical had been had been going on for some time, and had been exacerbated each time she had an HPV vaccine.  It is not entirely clear to me how long she has been symptomatic with her MS. 11/10/08-records received for DOS 8/23-8/29/08-DC DX: Multiple sclerosis. Anxiety. Presented with dizziness, generalized weakness and weakness of lower extremities. Summer 4/2008 after receiving HPV4 C/O pain in right eye and blurriness, light bothered the eye and had floaters. Significant fatigue. Two months prior developed flu-like symptoms with muscle aches, headaches, low grade chills and fever. Seen in ED normal labs and thought to had a viral infection. Week later developed abdominal pain and burning with urination. Urinary tract infection. Developed unsteady walking and increased reflexes in legs.
The patient received more than 0.5 ml dose; Needle issue; A spontaneous report was received from pharmacist concerning a 35-year-old female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and the patient received more than 0.5 ml dose.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On an unspecified date, the patient received their second of two planned doses of mRNA-1273 (Lot/batch number: unknown) intramuscularly for prophylaxis of COVID-19 infection.   On an unspecified date, the patient received dose spilled out of the needle and down the patient's arm. The immunizer then drew up another dose and gave that to the patient and the patient received more than 0.5 ml dose. Treatment information was not provided.   The patient received both scheduled doses of mRNA-1273 prior to the events, therefore action taken with the drug in response to the events was not applicable.   The outcome of the event the patient received more than 0.5 ml dose was considered recovered.; Reporter's Comments: This report refers to a case of accidental overdose and syringe issue for mRNA-1273, lot # unknown, with no associated AEs.
Broke out in hives less than one hour after administration. An antihistamine was administered. She does not currently have hives, but the antihistamine is still in her system, as it was a 24 hr. one.
Moderna COVID-19 Vaccine EUA. Severe headache began around 6-7 hours after vaccination. I began to have chills shortly after. Approximately 13 hours after vaccination, I began to feel nauseous, dizzy, and shaky along with my earlier symptoms. I felt like I was going to faint with blurred vision and ringing in my ears even while lying down. I started sweating along with the chills. The dizziness and nausea subsided after approximately two hours. The headache lasted approximately 48 hours after the vaccination.
Patient was vaccinated with Janssen vaccine. After the fifteen minute observation period, Patient complained of dizziness and was medically assessed. During the assessment, the patient presented with hypertension, but all other vitals signs were normal. There were no signs of allergic reaction. Patient was transported by the Fire Department to Medical Center.
no additional AE; Nurse reporting that MMRII was administered on 8/23/2022 with a labeled expiry of 8/18/2022. No temperature excursion involved. No additional information provided. No additional AE/PQC reported at time of call.; This spontaneous report has been received from a nurse concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history, drugs reactions or allergies and concomitant medications were not provided.  On 23-AUG-2022, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live, recombinant human albumin (rha) (M-M-R II) subcutaneous injection, 0.5  milliliters (mL), administered subcutaneously (valid lot number T027937 with an expiration date on 18-AUG-2022) (strength, frequency, and anatomical injection site were not provided) for prophylaxis (expired product administered), and sterile diluent (STERILE DILUENT)  (valid lot number T032311 with an expiration date on 05-MAY-2023).  No additional adverse event (AE) was reported.
PAPULAR RASH WITH PUSTULAR ROOF AND SOME VESICULAR RASH WITH CRUST WITH ERYTHEMA
J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 11/20/2022 CARDIOMEGALY J96.92 HYPERCAPNIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/19/2022 CARDIOMEGALY
Severe swelling, redness, pain, and itchiness at injection site one week later accompanied by low grade fever and fatigue.
Moderna use for COVID-19 under Emergency Use Authorization (EUA): Patient received injection in Right Delta on March 17, 2022. He is still complaining of pain at the injection site. He states it became swollen as typically seen but a know remains.
Severe rash to arms and legs, seen by dermatologist who determined rash was probably Giannoti Crosti caused by Hep B vaccinee.
Pt reports receiving COVID vaccine at 1500 and then feeling her lips and tongue swelling and itching. Pt. given Solu- Medrol 125mg/2mL IM to right gluteal and Benadryl 50mg/mL IM to left gluteal. Pt continue to be observed and symptoms improved. Pt. discharged home with husband and informed to go to ER if symptoms worsen.
Severe reflux within two days of vaccine; Severe abdominal pain and probable gastric bleed within 6 days of vaccine; Daily heart palpitations within two weeks of vaccine; Two acute strokes within a month of vaccine and a third stroke event after the first two acute strokes causing paralysis on right side and noticeable cognitive dysfunction.
Swollen lymph nodes in neck, so severe they caused difficulty and pain swallowing, and pain when tuning head. Swelling was not relieved by ice or ibuprofen.  Required a 6 day steroid treatment.
Headache, Fever, UrticariaPruritus, NauseaVomiting, per patient: "fever 102... Tylenol that brings it down to 99.7, severe H/A, N/V, Hoarseness, tongue itching"
swollen under armpit; swollen and red injection site; swollen and red injection site; This is a spontaneous report from a contactable consumer (patient).  A 25-year-old female patient received BNT162b2(PFIZER- BIONTECH COVID-19 mRNA VACCINE, Lot number: not reported), via an unspecified route of administration in the left arm on 21Mar2021 at 08:30 (at the age of 25-years-old) as dose number unknown, single  for COVID-19 immunisation.  The patient medical history was not reported. Concomitant medication(s) included sertraline hydrochloride (ZOLOFT). Prior to vaccination, the patient was not pregnant, not diagnosed with COVID-19, did not receive any other vaccines within 4 weeks. Since the vaccination, has the patient has not been tested for COVID-19. On an unknown date, the patient experienced swollen under armpit and swollen and red injection site. No therapeutic measures were taken for the adverse events. The clinical outcome of the events swollen under armpit and swollen, and red injection site was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained
Pt vaccinated intradermally.  No wheal formation.  Pt successfully revaccinated
swelling under my arm; Pain, Pain under the arm; rash lower chest; Small red patch under arm; This case was reported by a consumer via interactive digital media and described the occurrence of swelling in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2022, the patient received the 1st dose of Shingrix. In July 2022, less than a week after receiving Shingrix, the patient experienced swelling, axillary pain, rash and red rash. On an unknown date, the outcome of the swelling was unknown and the outcome of the axillary pain and red rash were not recovered/not resolved and the outcome of the rash was recovered/resolved.   It was unknown if the reporter considered the swelling, axillary pain, rash and red rash to be related to Shingrix.     Additional Information: GSK Receipt Date: 04-JUL-2022 Reporter's Comments: This case was reported by patient via interactive digital media. The patient received a first dose of Shingrix 3 three days ago (the day before reporting) and experienced swelling under arm, pain, also got a rash on the lower area of chest. The rash had subsided but there was a small red patch and pain under the arm. The patient asked was this normal. Additional Supportive Information: The follow-up would not possible as no contact details were available.
Extreme fatigue; Dizziness; Nausea at times; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Extreme fatigue), DIZZINESS (Dizziness), NAUSEA (Nausea at times) and HEADACHE (Headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 2 dosage form. On an unknown date, the patient experienced FATIGUE (Extreme fatigue), DIZZINESS (Dizziness), NAUSEA (Nausea at times) and HEADACHE (Headache). At the time of the report, FATIGUE (Extreme fatigue), DIZZINESS (Dizziness), NAUSEA (Nausea at times) and HEADACHE (Headache) outcome was unknown.            No treatment medication was reported by the reporter. No concomitant medications were reported. Chatbot case. Reporter stated that ,"on Sunday her husband received second vaccine and still have fatigue, dizziness, nausea at times, and headache".
Covid 19 infection/ Congestion; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Covid 19 infection/ Congestion) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    There was no reported medical history.  Concurrent medical conditions included Rheumatoid arthritis.   On 24-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Apr-2022, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. In 2022, the patient experienced COVID-19 (Covid 19 infection/ Congestion). At the time of the report, COVID-19 (Covid 19 infection/ Congestion) had not resolved.            Concomitant Drugs Not Reported. Humira was available in the form of solution for injection in pre-filled pen. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The reporter opinion of causality for the events of Respiratory tract congestion was not provided. No treatment details were reported.  Company Comment: This spontaneous case concerns a 33-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious AESI of COVID-19 unspecified days after the third dose of mRNA-1273 vaccine. No further details on clinical course, other lab test results and treatment received were reported. The outcome of the event was reported as not resolved. Current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to MOD-2022-640741 (Patient Link).; Sender's Comments: This spontaneous case concerns a 33-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious AESI of COVID-19 unspecified days after the third dose of mRNA-1273 vaccine. No further details on clinical course, other lab test results and treatment received were reported. The outcome of the event was reported as not resolved. Current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
Left arm redness, swelling, pain. Treated with KEFLEX and prednisone.
Started with flushed/itchy face after receiving vaccine on 10/14/14 took loratadine 10 mg daily x 2 days until symptoms resolved.
Patient had swelling in throat after 15 to 20min, epipen was administered, patient was transported by ambulance to hospital.  Lipid carrier component was identified as agent causing reaction, patient returned the next day with prescriptions for allergic reaction and appeared to be fine.
Redness and itching around injection site approx. 8 hours after injection.  Pt applied ice and took benadryl at bedtime.  Redness cleared from injection site the next day but had moved to inside of arm down to elbow.   Patient will continue to apply ice, bendryl, and ibuprofen.
Within the first 24 hours I developed a large, red inflamed area about 4" from top to bottom, at the site of the injection (right arm).  It became very red with a raised surface and very warm to the touch.  I took two Advil and two doses of Benadryl 25 mg each, and it has subsided somewhat, but is still sore 72 hours later.
Information has been received from a LPN concerning a 27 month old white female with no medical history and no known allergies who on 04/11/02 was vaccinated SC in the right arm with a first dose of varicella virus vaccine live (Lot # 639901/1152L).  There was no concomitant medication.  On 08/06/03 at 15:00 the pt developed breakthrough chickenpox described as a multiple erythema base; some with vesicles (approximately 50 vesicles) and some crusted. The pt also developed a low grade fever, pruritis and fussiness. Unspecified medical attention was sought. Subsequently, the pt recovered. No product quality complaint as involved. It was also reported that this pt was vaccinated with a first dose of MMRII (manufacturer unknown) and at 12 months of age developed a fever and a rash (WAES # 0308USA02494).  It was also reported that an 18 month old male was vaccinated SC in the right arm with a dose of varicella virus vaccine live (Lot # 639901/1152L) and developed breakthrough chickenpox (WAES # 0308USA00828).  No further information is expected.
Within 12 hrs of vaccine. L arm at vaccine swollen, red and painful.  Treated with BENADRYL.  Also, had a fever.
This spontaneous report as received from a Licensed Vocational Nurse regarding 5 patients of unknown demographics. There was no information about pertinent medical history, drug reactions or drug allergies. On 27-AUG-2015, the patients were vaccinated with (Merck) PROQUAD lot# L005297 and expiry date: 17-AUG-2016, that was improperly exposed to defrost cycling. No adverse effect was reported. The outcome of the event was unknown. This is one of the several reports from the same reporter. Additional information has been requested.
Vomiting since 6:30 pm on 8/11/11 with diarrhea & chills today. 2 liters normal saline IV, ZOFRAN 4 mg IV x2, TORADOL 15mg IV x 2, lab work.
Visual Snow Syndrome (primarily palinopsia).   Saw multiple Neurologist, Neuro-optomologist, and other eye doctors / Vision Therapy.  Originally thought Topamax (which I had been on for over a year ) was the cause. I stopped topamax and symptoms did not improve.  Over the past 10 months symptoms have slightly improved (but not dramatically different). Possibly because of Vision Therapy.
Feeling "really sick"; This is a spontaneous report from non-contactable consumer (patient) via a Pfizer-sponsored program, COVAX Support. This female patient of unspecified age received a dose of BNT162B2 (TRADE NAME UNSPECIFIED; lot number unknown) via an unspecified route of administration on 01Mar2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient reported feeling really sick on an unspecified date; the patient also asked about other side effects. The clinical outcome of feeling really sick was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.